APA (7th ed.) Citation

Stein, C. A., Levin, R., Given, R., Higano, C. S., Nemeth, P., Bosch, B., . . . Dreicer, R. (2018). Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. Urologic Oncology, 36(2), 81.e9. https://doi.org/10.1016/j.urolonc.2017.10.018

Chicago Style (17th ed.) Citation

Stein, Cy A., Richard Levin, Robert Given, Celestia S. Higano, Paul Nemeth, Bill Bosch, Jillian Chapas-Reed, and Robert Dreicer. "Randomized Phase 2 Therapeutic Equivalence Study of Abiraterone Acetate Fine Particle Formulation Vs. Originator Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: The STAAR Study." Urologic Oncology 36, no. 2 (2018): 81.e9. https://doi.org/10.1016/j.urolonc.2017.10.018.

MLA (9th ed.) Citation

Stein, Cy A., et al. "Randomized Phase 2 Therapeutic Equivalence Study of Abiraterone Acetate Fine Particle Formulation Vs. Originator Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: The STAAR Study." Urologic Oncology, vol. 36, no. 2, 2018, p. 81.e9, https://doi.org/10.1016/j.urolonc.2017.10.018.